Advanced search
Publication Cover
Journal of Medical Economics Volume 25, 2022 - Issue 1
Submit an article Journal homepage
3,763
Views
18
CrossRef citations to date
0
Altmetric
Oncology

Cost-effectiveness analysis of sintilimab + chemotherapy versus camrelizumab + chemotherapy for the treatment of first-line locally advanced or metastatic nonsquamous NSCLC in China

Mingjun Ruia School of International Pharmaceutical Business, China Pharmaceutical University, Nanjing, Jiangsu, People’s Republic of China;b Center for Pharmacoeconomics and Outcomes Research, China Pharmaceutical University, Nanjing, Jiangsu, People’s Republic of China
,
Zhengyang Feia School of International Pharmaceutical Business, China Pharmaceutical University, Nanjing, Jiangsu, People’s Republic of China;b Center for Pharmacoeconomics and Outcomes Research, China Pharmaceutical University, Nanjing, Jiangsu, People’s Republic of China
,
Yingcheng Wanga School of International Pharmaceutical Business, China Pharmaceutical University, Nanjing, Jiangsu, People’s Republic of China;b Center for Pharmacoeconomics and Outcomes Research, China Pharmaceutical University, Nanjing, Jiangsu, People’s Republic of China
,
Xueke Zhanga School of International Pharmaceutical Business, China Pharmaceutical University, Nanjing, Jiangsu, People’s Republic of China;b Center for Pharmacoeconomics and Outcomes Research, China Pharmaceutical University, Nanjing, Jiangsu, People’s Republic of China
,
Aixia Maa School of International Pharmaceutical Business, China Pharmaceutical University, Nanjing, Jiangsu, People’s Republic of China;b Center for Pharmacoeconomics and Outcomes Research, China Pharmaceutical University, Nanjing, Jiangsu, People’s Republic of China
,
Haikui Sunc Innovent Biologics (Suzhou) Co., Ltd, Suzhou, Jiangsu, People’s Republic of China
&
Hongchao Lia School of International Pharmaceutical Business, China Pharmaceutical University, Nanjing, Jiangsu, People’s Republic of China;b Center for Pharmacoeconomics and Outcomes Research, China Pharmaceutical University, Nanjing, Jiangsu, People’s Republic of ChinaCorrespondence[email protected]
 show all
Pages 618-629 | Received 23 Dec 2021, Accepted 25 Apr 2022, Published online: 15 May 2022

Related Research Data

Cost-effectiveness analysis of sintilimab + chemotherapy versus camrelizumab + chemotherapy for the treatment of first-line locally advanced or metastatic nonsquamous NSCLC in China
Source: Taylor & Francis

Linking provided by 

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.